Dr. Dirk-Jan van Ginkel and Dr. C Michael Gibson Discuss: POPular PAUSE TAVI – Continuation or interruption of oral anticoagulation during TAVI? August 31, 2024 Disclosures: TBD
Dr. Johanne Silvain, Dr. Gilles Montalescot and Dr. C Michael Gibson Discuss: ABYSS – Beta blocker interruption in post-myocardial infarction patients August 30, 2024 Disclosures: TBD
Dr. Rasha Al-Lamee and Dr. C. Michael Gibson Present: An Interventional Cardiology 2023 Year in Review December 28, 2023 Disclosures: TBD
Dr. Paul Ridker and Dr. C. Michael Gibson Discuss: CLEAR OUTCOMES subanalysis on predicting CV events November 13, 2023 Disclosures: TBD
Dr. Richard Wright and Dr. C. Michael Gibson Discuss: The Genetic / Mendalian randomization (natures randomized trial) data that supports the efficacy of Acoramadis in amyloidosis and the potential for amyloid regression with therapy November 13, 2023 Disclosures: TBD
Dr. Charalambos Antoniades and Dr. C. Michael Gibson Discuss: Novel AI Technology to Improve Risk Stratification of Patients Without Obstructive Coronary Artery Disease Undergoing CCTA: The Oxford Risk Factors and Non-Invasive Imaging (ORFAN) Study November 13, 2023 Disclosures: TBD
Dr. Daniel Judge and Dr. C. Michael Gibson: Acoramidis from bench to bedside November 12, 2023 Disclosures: TBD
Dr. Steven Nissen and Dr. C. Michael Gibson Discuss: Efficacy and Safety of Lepodisiran: An Extended Duration Short-Interfering RNA Targeting Lipoprotein (a) November 12, 2023 Disclosures: TBD
Dr. Andrew Bellinger, Dr. Sek Kathiresan and Dr. C. Michael Gibson Discuss: Safety and Pharmacodynamic Effects of VERVE-101, an Investigational DNA Base Editing Medicine Designed to Durably Inactivate the PCSK9 Gene and Lower LDL Cholesterol – Interim Results of the Phase 1b heart-1 Trial November 12, 2023 Disclosures: TBD
Dr. Nina Becher and Dr. C. Michael Gibson Discuss: Efficacy and Safety of Anticoagulation With Edoxaban in Patients With AHRE Durations ≥24 Hours. The NOAH-AFNET 6 Trial November 12, 2023 Disclosures: TBD